Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBarr (A.G.) Regulatory News (BAG)

Share Price Information for Barr (A.G.) (BAG)

Share Price is delayed by 15 minutes
Get Live Data
613.00    6.00 (0.99%)
Bid:
610.00
Ask:
612.00
Spread: 2.00 (0.328%)
Market Cap: £680.28m
BAG Live PriceLast checked at - London Stock Exchange

Intraday Barr (A.G.) Share Chart

Trading Statement

29 Jul 2025 07:00

RNS Number : 8564S
Barr(A.G.) PLC
29 July 2025
 

IMMEDIATE RELEASE 29 July 2025

A.G. BARR p.l.c

("A.G. BARR" or "the Company")

 

Trading Update

 

Continued revenue & profit growth; Full Year expectations unchanged

 

A.G. BARR p.l.c., the multi-beverage business with a portfolio of market-leading UK brands including IRN-BRU, Rubicon, Boost and FUNKIN, today announces a trading update for the 26 weeks ended 26 July 2025 (H1 2025/26).

H1 2025/26 Trading

H1 2025/26 revenue is expected to be c.£228m, c.3% up on the prior year (H1 2024/25: £221.3m). Overall, the Company's trading momentum increased as H1 progressed, with several record volume weeks in Q2.

Brand revenue performance was led by Boost which delivered strong double-digit growth. IRN-BRU and Rubicon were flat in H1, with a stronger performance in Q2. FUNKIN saw continued off-trade growth partly mitigating challenges in on-trade, with the overall trend improving during H1 and positive in Q2. 

H1 adjusted operating margin is anticipated to be ahead of last year at c.15.0% (H1 2024/25: 13.0%) driven by improved manufacturing efficiencies, on-going benefits from our strategic business improvement initiatives and continued disciplined cost management.

Strategy Update

We are pleased to announce the Company has acquired a 50.1% equity stake in Innate-Essence Ltd, for an initial consideration of £15 million. Innate-Essence is the home of The Turmeric Co., a leading brand in the functional shots market, as well as a number of other speciality health drinks.

This is consistent with the Company's strategy of acquisitions and innovation in high growth, health focused, functional beverage categories. The investment has been funded from the Company's net cash position. It is not expected to have a significant impact on revenue or profit in the current financial year.

The Company has also concluded the sale of the Strathmore brand and the Forfar production site to Tŷ Nant, negatively impacting revenue in the short-term but not profit.

Full Year Outlook

Our revenue and profit growth expectations for the full year are unchanged. We are confident that H2 will see a strong rate of year-on-year revenue growth. We have made excellent progress with operating margin during H1 and expect to deliver a full year result in line with expectations after taking into account a planned higher level of marketing activity in H2.

Euan Sutherland, Chief Executive Officer, commented:

"We are pleased to report continued revenue growth and strong profit growth in the first half of the financial year. Trading improved during H1 and we enter H2 with strong momentum and continued progress on margin improvement as our strategic initiatives continue to deliver. I am also excited about our expansion into the functional beverage segment working alongside Thomas Robson-Kanu and the Innate-Essence team. Our full year guidance remains unchanged and in line with market expectations."

For more information, please contact :

A.G. BARR  MHP GROUP

0330 390 3900 07801 894 577

Euan Sutherland, Chief Executive Officer agbarr@mhpgroup.com

Stuart Lorimer, Chief Finance and Operating Officer Oliver Hughes

Ewan Dytch, Corporate Finance Director Rachel Farrington

Veronica Farah

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUWOSRVSUBUAR
Date   Source Headline
24th Jul 20191:36 pmRNSDirector/PDMR Shareholding - clarification
24th Jul 201910:44 amRNSDirector/PDMR Shareholding - replacement
24th Jul 20197:00 amRNSTransaction in Own Shares
23rd Jul 20199:38 amRNSDirector/PDMR Shareholding
23rd Jul 20199:37 amRNSDirector/PDMR Shareholding
16th Jul 20197:00 amRNSPre-close trading update
8th Jul 201911:39 amRNSDirector/PDMR Shareholding
11th Jun 20191:14 pmRNSDirector/PDMR Shareholding
11th Jun 20191:13 pmRNSDirector/PDMR Shareholding
10th Jun 201912:40 pmRNSDirector/PDMR Shareholding
10th Jun 201912:38 pmRNSDirector/PDMR Shareholding
10th Jun 201912:37 pmRNSDirector/PDMR Shareholding
10th Jun 201912:36 pmRNSDirector/PDMR Shareholding
10th Jun 201912:29 pmRNSDirector/PDMR Shareholding
7th Jun 20197:00 amRNSMinority investment in STRYYK
31st May 201912:42 pmRNSAGM Statement
29th May 20198:04 amRNSHolding(s) in Company
9th May 20193:58 pmRNSDirector/PDMR Shareholding
3rd May 20191:18 pmRNSDirector/PDMR Shareholding
17th Apr 20199:24 amRNSAnnual Report and Accounts and Notice of AGM
4th Apr 20193:25 pmRNSDirector/PDMR Shareholding
2nd Apr 20191:51 pmRNSDirector/PDMR Shareholding
2nd Apr 20191:43 pmRNSDirector/PDMR Shareholding
26th Mar 20197:00 amRNSFinal Results
8th Mar 20191:11 pmRNSDirector/PDMR Shareholding
8th Mar 20199:36 amRNSHolding(s) in Company
15th Feb 20197:30 amRNSTransaction in Own Shares
8th Feb 20199:39 amRNSDirector/PDMR Shareholding
8th Feb 20197:30 amRNSTransaction in Own Shares
5th Feb 20197:30 amRNSTransaction in Own Shares
25th Jan 201912:25 pmRNSClosed period repurchase programme
25th Jan 20197:00 amRNSTrading Update
15th Jan 201910:48 amRNSNotice of Pre-Close Trading Update
9th Jan 201912:38 pmRNSDirector/PDMR Shareholding
10th Dec 20181:32 pmRNSDirector/PDMR Shareholding
8th Nov 201812:14 pmRNSDirector/PDMR Shareholding
29th Oct 201812:26 pmRNSDirector/PDMR Shareholding
29th Oct 201812:24 pmRNSDirector/PDMR Shareholding
29th Oct 201812:22 pmRNSDirector/PDMR Shareholding
29th Oct 201812:19 pmRNSDirector/PDMR Shareholding
25th Oct 20187:00 amRNSBoard Appointment
23rd Oct 20187:30 amRNSTransaction in Own Shares
17th Oct 20187:30 amRNSTransaction in Own Shares
16th Oct 20187:30 amRNSTransaction in Own Shares
12th Oct 20187:44 amRNSTransaction in Own Shares
10th Oct 20187:30 amRNSTransaction in Own Shares
8th Oct 20181:15 pmRNSDirector/PDMR Shareholding
8th Oct 20187:30 amRNSTransaction in Own Shares
5th Oct 20187:30 amRNSTransaction in Own Shares
4th Oct 20187:30 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.